Begin main content


Last Updated: January 24, 2020
Result type: Reports
Project Number: SR0640-000
Product Line: Common Drug Review

Generic Name: eculizumab

Brand Name: Soliris

Manufacturer: Alexion Pharma Canada Corp.

Indications: Neuromyelitis optica spectrum disorder

Manufacturer Requested Reimbursement Criteria1: ​For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Submission Type: New Indication

Project Status: Pending

Call For Patient Input: January 24, 2020

Patient Input Closed: March 16, 2020

Anticipated Date: February 24, 2020

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback